Eli Lilly and Company (LLY) on Decifer

Decifer ranks LLY number 176 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 30% and those returns have been improving.
• Revenue is growing about 45% a year, profits grew 96% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Its profit margin and growth are both unusually high right now compared to its own history, the kind of combination that often fades once conditions normalize.
• Returns around 30% and revenue growing 45% are exceptional, but the high margin and growth mix often fades and it holds no stated role in our worldview.

The current read

The evidence on LLY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full LLY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.